Professor Gary Collins, Professor Cyrus Cooper, Professor Fiona Powrie and the late Professor Doug Altman have been named on the annual Highly Cited Researchers™️ 2020 list from Clarivate.

Profile pictures of Professor Gary Collins, Professor Cyrus Cooper, Professor Fiona Powrie and Professor Doug Altman

The highly anticipated annual list identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade. Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.

Gary's research interests are primarily focused on methodological aspects surrounding the development and validation multivariable prediction (prognostic) models (design and analysis) and he has published extensively in this area. 

Cyrus leads an internationally competitive programme of research into the epidemiology of musculoskeletal disorders, most notably osteoporosis.

Fiona is Director at the Kennedy Institute of Rheumatology, and her research interests include characterisation of the interaction between the intestinal microbiota and the host immune system and how this mutualistic relationship breaks down in inflammatory bowel disease.

The late Doug Altman’s varied research interests included the use and abuse of statistics in medical research, studies of prognosis, regression modelling, systematic reviews and meta-analysis, randomised trials, and studies of medical measurement. 

Head of Department at NDORMS, Professor Andrew Carr, said: “My congratulations go to my colleagues on achieving global recognition of excellence for their research. We can be proud of our strong multi-disciplinary research base and the impact it has on translational research to improve patients’ quality of life.” 

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.